Severity
Critical
FDA Drug recall · Reported December 4, 2013
Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined that J.R. Jack Rabbit Male Enhancement product was found to contain two undeclared …
Jack Rabbit, Inc recalled J.R. Jack Rabbit All Natural Herbal Supplement, One tablet can last 24-72 hours, 4-count… - a critical-severity action.
J.R. Jack Rabbit All Natural Herbal Supplement, One tablet can last 24-72 hours, 4-count… was recalled by Jack Rabbit, Inc in December 4, 2013. Reason: Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined that J.R. Jac…. Check the official notice for the remedy. Verify recall #D-021-2014 with the FDA Drug before acting.
The recall
Jack Rabbit, Inc issued this critical-severity FDA Drug recall-Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined that J.R. Jac….
Sourced from official FDA Drug enforcement records. Verify recall #D-021-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-021-2014) was formally reported on December 4, 2013, with the manufacturer initiating the action on August 12, 2013. It is classified under Critical severity (Class I), with a current status of Terminated. Jack Rabbit, Inc is listed as the recalling firm, operating out of Melbourne, FL. Federal records list the affected scope as 1,000 Tablets.
The documented reason for this recall is: Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined that J.R. Jack Rabbit Male Enhancement product was found to contain two undeclared active pharmaceutical ingredients: sild… Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
1,000 Tablets
Related Recalls
6
5 from same agency
J.R. Jack Rabbit All Natural Herbal Supplement, One tablet can last 24-72 hours, 4-count tablets per blister pack, Order at: www.jackrabbitfourpack.com, Jack Rabbit Inc., 4355 Dow Road, Melbourne, FL 32934
Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined that J.R. Jack Rabbit Male Enhancement product was found to contain two undeclared active pharmaceutical ingredients: sildenafil and tadalafil.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-021-2014 |
| Date reported | December 4, 2013 |
| Date initiated | August 12, 2013 |
| Recalling firm | Jack Rabbit, Inc |
| Firm location | Melbourne, FL |
| Affected scope | 1,000 Tablets |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported December 4, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.